Clinical Trial Update: A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sequential addition of insulin aspart versus further dose escalation of the fixed-dose combination insulin degludec/liraglutide in adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoLog (insulin aspart)
• Tresiba (insulin degludec)
• Victoza (Liraglutide)
• Xultophy (insulin degludec and liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2017-01-20